Revenue and profitability
- QQ4 2024 Revenue: 48,266 USD; YoY change: -61.57%; QoQ change: -91.90%
- Gross Profit: 225,356 USD; Gross Margin: 4.67% (anomalous given negative cost of revenue entry of -177,090 USD; implies unusual accounting items in the period)
- EBITDA: -3,145,832 USD; EBITDA Margin: -65.18%
- Operating Income: -2,649,796 USD; Operating Margin: -54.90%
- Net Income: -2,650,717 USD; Net Margin: -54.92%
- EPS: -0.19; EPS Diluted: -0.19; YoY EPS change: +13.64%; QoQ EPS change: -58.33%
Cash flow and liquidity
- Operating cash flow: -1,524,104 USD
- Free cash flow: -1,553,406 USD
- Net cash from financing activities: +1,560,724 USD
- Net change in cash: +7,318 USD
- Cash at end of period: 87,403 USD
Balance sheet and leverage
- Total assets: 3,115,253 USD; Total liabilities: 2,429,300 USD; Total stockholders’ equity: 685,953 USD
- Current assets: 1,041,660 USD; Current liabilities: 1,412,370 USD; Current ratio: 0.74; Quick ratio: 0.46; Cash ratio: 0.062
- Long-term debt: 1,016,930 USD; Total debt: 1,365,040 USD
- Retained earnings: -82,799,324 USD; Shareholders’ equity: 685,953 USD
- Asset turns and efficiency: Receivables turnover 2.59x; Inventory turnover -0.454x; Asset turnover 0.0155x
Valuation and market context
- Price-to-Sales (from ratios): ~289.43x; Price-to-Book: ~20.37x; Enterprise value multiple: ~-4.85x (negative EBITDA/enterprise value dynamics typical for micro-cap loss-making tech/biotech-like device issuers)
- The quarter reflects a platform with limited near-term profitability but potential upside if Spryng adoption and pipeline devices gain traction. In the peer landscape, peers exhibit wide dispersion in gross margins and profitability, underscoring the high-risk, high-variance nature of micro-cap healthcare device equities.